Pharma Sector

Indian drugmakers are reviewing shipment schedules and inventories for West Asia as escalating tensions threaten sea and air routes, raising freight costs and risking supply delays

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

Planning to outsource GMP audits to agencies certified by QCI; onboard 1,500 experts to review drug applications

Morepen Labs has secured a ₹825 crore multi-year CDMO mandate from a global pharma major, with supplies set to begin in 4-5 months and execution running through Q1 FY27

Aurobindo Pharma is looking to ramp up the production of Penicillin-G to over 10,000 metric tonnes on an annual basis over the next 12 months, according to company CFO S Subramanian. The Hyderabad-based drug maker also expects its China-based manufacturing plant to break even in EBITDA in Q4 and meaningfully contribute to the bottom-line EBITDA in the next year. "The ramp-up of the facility (Pen-G) is progressing in line with expectations and is well-positioned to deliver a meaningful uplift in profitability over time. Based on our current production level, we expect to produce more than 10,000 metric tonnes on an annualised basis over the next 12 months," Subramanian told analysts in a call. The company's Pen-G facility, located in a SEZ at Kakinada in Andhra Pradesh, is expected to touch production capacity of 15,000 metric tonnes per annum over a period of time. "It is important to note that the yield levels are steady and improving consistently over time," Subramanian said. Th

The commerce ministry on Saturday said the country's pharma exports grew 9.4 per cent in 2024-25 to USD 30.47 billion and the industry is aiming for a double-digit expansion in 2026-27. Issues pertaining to pharmaceuticals exports were discussed between the government officials and industry during Chintan Shivir in Ahmedabad. The sector, currently valued around USD 60 billion, is projected to reach USD 130 billion by 2030. India ranks third globally by volume, with medicines exported to over 200 markets, and more than 60 per cent of exports destined for stringent regulatory markets. The US accounts for 34 per cent and Europe for 19 per cent of India's pharmaceutical exports. "The interaction underlined the government's focus on enabling conditions for sustained export acceleration, with industry indicating readiness to target double-digit growth in 2026-27," it said. It added that exporters were also apprised of opportunities arising from recent trade engagements with key partner

India and Brazil are poised to sign private-sector agreements across pharma, aerospace, ethanol and trade during President Lula's visit, as both nations expand cooperation in critical minerals and AI

The government has disbursed Rs 28,748 crore under PLI schemes for 14 sectors, including electronics and pharma, since the launch of the support measure to boost domestic manufacturing, the government on Friday said. In 2021, the government announced Production-Linked Incentive (PLI) schemes for 14 sectors with an outlay of Rs 1.97 lakh crore. As many as 836 applications across 14 sectors, involving cumulative investment of over Rs 2.16 lakh crore, have been approved under the production linked incentive (PLI) scheme as of December 2025, It said that these sectors have registered a cumulative sales of over Rs 20.41 lakh crore, and exports of over Rs 8.3 lakh crore, the commerce and industry ministry said. It has generated employment for more than 14.39 lakh people. "Rs 28,748 crore (has been) disbursed as on December 31, 2025," it said. The 14 sectors include large scale electronics manufacturing, IT hardware, bulk drugs, medical devices, pharmaceuticals, telecom and networking .

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Pharma leaders at BioAsia said AI is accelerating discovery and documentation, doubling pipelines at some firms, though its impact on clinical costs and timelines remains uneven

India's pharma market is estimated to touch $120 billion by 2030 while Uttar Pradesh accounts for roughly 17 percent of domestic sales

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory reform and AI to power the next growth phase

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year

USV, a pharmaceutical and biotechnology company, will acquire a 79 per cent stake in Wellbeing Nutrition at a valuation of Rs 1,583 crore. USV has signed a definitive agreement to acquire a 79 per cent equity stake in Nutritionalab Pvt Ltd, which owns "Wellbeing Nutrition", according to a joint statement. This includes 35 per cent from the founder Avnish Chhabria and 44 per cent from existing shareholders. Its investors -- Early backers Fireside Ventures and Hindustan Unilever -- will divest their collective 40 per cent stake. This Rs 1,583 crores all-cash transaction represents the largest exit in India's health and wellness startup space to date, it added. This strategic expansion of USV, a leading player in diabetes and cardiac care, into consumer wellness is aligned with its expansion across the healthcare continuum. "The addition of Wellbeing Nutrition reinforces USV's evolution into a comprehensive healthcare powerhouse spanning both therapeutic excellence and consumer ...

ECDS, a company specialised in sustainable development technologies, on Wednesday announced it will set up a medical equipment manufacturing unit in Ujjain with an initial investment of Rs 780 crore under a joint venture with three South Korean companies. According to the company, this will be its first factory in India. "We have submitted a proposal to the state government to set up a unit on 15.60 acres of land in the Medical Equipment Park in Vikram Udyogpuri, Ujjain, of which we have already acquired 1.5 acres. This will be our first unit in the country," said Rajesh Bharadwaj, director of ECDS's Indian branch. He said construction will begin this year with an initial investment of Rs 780 crore, and the first phase of production will start by April 2027. "In the first phase, efforts will be made to provide employment to approximately 500 people," Bharadwaj told reporters in Indore. He said ECDS has partnered with three South Korean companies in a 50:50 joint venture to impleme

JM Financial raised concerns around Mankind Pharma's recent BSV acquisition, which was executed at a high valuation and is expected to dilute return on capital

Pharma-focused Budget 2026 measures could help India move beyond generics by boosting biologics, biosimilars, regulatory capacity and early-stage innovation, analysts say

The US market stayed a weak spot for Indian pharma companies in Q3FY26 amid sustained pricing pressure in generics, heightened competition and product-specific challenges

India's pharmaceutical exports to the US are unlikely to see major tariff changes under the interim pact as Section 232 investigations continue, though medical devices may gain from better access